New estimates say that Medicare will spend tens of billions of dollars over nine years to cover weight-loss drugs.

Britain on Monday asked its antitrust regulator to make growth and investment a priority as the government sought to woo some ...

Chief Executive David Ricks told then-UK Health Secretary Victoria Atkins last December that the company’s new Alzheimer’s ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

If you're looking for two magnificent growth stocks to start your long-term portfolio (or add to a portfolio) and have $500 ...

Read which pharmaceutical companies are addressing the risk of muscle mass loss associated with popular weight loss drugs from Novo (NOVO) and Eli Lilly (LLY).

A pharmacist warns that off-brand Ozempic, Zepbound, and other weight loss products carry undisclosed risks for consumers.

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

FDA halts actions on makers of compounded drugs as it reviews decision to remove Eli Lilly's (LLY) weight loss drug ...

The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide from its ...

The U.S. Food and Drug Administration on Friday agreed to reconsider its recent decision barring drug compounders from ...